Introduction
Neural stem cells (NSCs) are self-renewing and multipotent cells, which allow some degree of regeneration and plasticity in the adult brain. Although their presence in the subventricular zone surrounding the adult lateral ventricle of the telencephalon and in the subgranular zone of the dentate gyrus has been shown in vivo and their characteristics analyzed in vitro, the existence of cells with similar properties in the postnatal cerebellum has been suggested only recently (Lee et al., 2005) . It is intriguing to think that NSCs populating specific brain areas might be a novel putative cell of origin of brain tumors. Preliminary evidence to support this hypothesis has been provided by a study which showed that stimulation of subventricular zone stem cells with platelet-derived growth factor, a signaling pathway known to be deregulated in brain tumors of glial origin, led to hyperplastic growth (Jackson et al., 2006) . More recently, two papers have shown that inactivation of the tumor suppressor genes p53 and PTEN or Nf1 and p53 in subventricular zone stem/progenitor cells induces high-grade astrocytomas (Zheng et al., 2008; Alcantara Llaguno et al., 2009) . However, both studies have used either hGFAP-driven Cre expression or intraventricular adenovirus-mediated Cre delivery to target progenitor cells and these approaches do not allow to target stem cells specifically. In fact, other reports showed that postnatal NSCs are remarkably resistant to neoplastic transformation. Foroni et al. (2007) were able to culture these cells in vitro with the neurosphere (NS) assay for over a year and did not detect any evidence for neoplastic transformation in vivo, even after transduction of the cells with Myc and Ras oncogenes (Foroni et al., 2007) .
Medulloblastomas are heterogeneous neoplasms characterized by variable prognosis and response to therapy. Currently, the best predictors of prognosis are the patient's age at diagnosis, the extent of postoperative residual tumor and the presence of metastatic disease. However, these clinical parameters have limitations in their predictive value and do not provide mechanistic insights into the pathogenesis of a specific neoplasm or into the response of the tumor to therapy, as biomarkers would do. Very few biomarkers have been identified for medulloblastomas, but they have not yet been extensively validated or are highly controversial (Crawford et al., 2007) .
A subset of medulloblastomas is believed to originate from committed granule cell progenitors (GCPs) located in a secondary germinal layer unique to the developing cerebellum, the external granular layer (EGL), that will give rise to granule neurons (reviewed in Behesti and Marino, 2009) . Heterozygosity for the Ptc gene, a key member of the Shh signaling pathway, has been shown to predispose to medulloblastoma formation in a hereditary tumor syndrome, the Gorlin Syndrome (Hahn et al., 1996; Johnson et al., 1996) and in genetically engineered mice (Goodrich et al., 1997) . Recently, acquisition of granule cell precursor identity has been suggested to be critical for medulloblastoma formation in mouse models, where aberrant Shh pathway activation was promoting tumorigenesis (Schuller et al., 2008; Yang et al., 2008) . These models have significantly contributed to our understanding of the pathogenesis of these neoplasms in young children (Marino et al., 2000; Weiss et al., 2002; Eberhart, 2003; Tong et al., 2003) . However, the occurrence of medulloblastomas in older children and adults, where such progenitor cells are no longer present, is not explained by these models. Moreover, mutations in the PTC gene and other related Shh pathway members have been found only in a minority of sporadic medulloblastomas (25%; Zurawel et al., 2000) .
We have previously developed a mouse model of medulloblastoma by selective inactivation of the tumor suppressor genes Rb and p53 in GCPs of the EGL. After a latency of 20 weeks medulloblastomas occur in the cerebellum with 100% penetrance. These tumors show remarkable similarities to the large cell anaplastic variant of human medulloblastoma, including similar histology, highly aggressive behavior (Marino et al., 2000) and acquisition of additional genetic mutations mainly affecting N-Myc (Shakhova et al., 2006) . Here we have taken advantage of this powerful experimental system in which medulloblastomas arise with full penetrance when permissive cells are targeted to address the question of whether postnatal cNSCs can function as medulloblastoma-initiating cells and whether different ontogenetic mechanisms can have a role in explaining the heterogeneity of these tumors in humans.
Results
Cerebellar neural stem cells (cNSCs) were isolated from postnatal day 7 (P7) cerebella by magnetic-activated cell sorting using anti-prominin/CD133 beads. This is currently the best characterized marker to isolate NSCs of neuroepithelial (NE) origin (Corti et al., 2007) and has been shown to be expressed in both white matter cNSC and in periventricular cells of the fourth ventricle (Lee et al., 2005 and GENSAT) .
First, to assess whether GCPs were present in the CD133 þ fraction, we applied this method to the cerebella of P7 Math1-GFP mice, transgenic mice in which green fluorescent protein (GFP) expression is driven by the Math1 promoter, a helix-loop-helix transcription factor specifically expressed in GCPs (Figure 1a ; Lumpkin et al., 2003 Figure S1A , B). These data are in keeping with a considerable enrichment for cNSCs and precursors of non-granule cell lineage in the CD133 þ fraction. Upon plating, GFP þ cells, which were morphologically recognizable as GCPs, were seen in the CD133 À fraction (Figure 1b , left) however, no GFP positivity was detected in the NS that formed in the CD133 þ fraction (Figure 1b, right) . To further enrich for cNSC and to make sure that the residual GCPs were eliminated from the cultures, we repeatedly dissociated and replated (at least three times) NS arising in the CD133 þ fraction. Under continuous exposure to EGF and bFGF, only NSCs and highly undifferentiated progenitors proliferate, whereas committed precursors, such as GCPs and terminally differentiated cells are eliminated from the culture (Galli et al., 2008) . Flow cytometry analysis performed on single cells 24 h after splitting tertiary NS revealed no GFP þ cells (Figure 1c and Supplementary Figure S1D ). Morphological analysis of the cultures confirmed absence of GFP þ cells (Figure 1d ). Moreover, no GFP expression was noted in NS originating from these cells (quaternary NS) upon fixation and visual confocal analysis (Figure 1e ).
Neurospheres originating from the CD133 þ cells expressed stem cell markers, such as CD133, Nestin, Bmi1 and Sox2, in a proportion of the cells (Figure 1f ). These cells were capable of long-term self-renewal as assessed by repeated dissociation and replating in the same NS-forming culturing conditions (Supplementary Figure  S2) and were multipotent as assessed by their capacity to differentiate into neurons, oligodendrocytes and astrocytes when grown in a differentiation-inducing medium ( Figure 1g ). All experiments were repeated at least three times from three independent primary preparations.
Next, we isolated cNSCs from homozygous compound mutant mice carrying floxed alleles for Rb, p53 (Rajewsky et al., 1996; Marino et al., 2000) as well as Postnatal cerebellar stem cells and medulloblastoma R Sutter et al R26R-LacZ (Soriano, 1999) and deleted Rb and p53 in these cells by adenovirus-mediated Cre-induced recombination in vitro (Akagi et al., 1997) . (Meuwissen et al., 2003) , that the p53 locus is potentially less accessible for the Cre enzyme. Cell viability, as assessed by the Alamar blue assay, was significantly higher in NS lacking Rb and p53 as compared with control cells infected with Adeno-GFP ( Figure 2c ). Accordingly, the mutant cultures showed a higher number of NS with a larger diameter compared to controls ( Figure 2d ). We then assessed whether lack of Rb and p53 would influence the number of cells capable of giving rise to NS in these cultures. In a clonogenic assay, we found a significantly higher (twofold) number of quaternary NS arising from the same number of plated cells upon dissociation of tertiary NS ( Figure 2e ). Interestingly, we found a significant resistance to apoptosis of the cells in the mutant NS, as assessed by Annexin V staining and flow cytometry (5 compared to 18% in controls; Figure 2f ). Finally, mutant cNSCs still exhibited multipotency and were able to give rise to neurons, oligodendrocytes and astrocytes after induction of differentiation in vitro, as determined by immunostaining for astrocytic (glial fibrillary acidic protein, GFAP), oligodendroglial (O4) and neuronal (b III tubulin) markers, although they show a tendency to give rise to a lower number of differentiated cells (Figure 2g ). To exclude differences in viral toxicity between the two viruses, we performed all experiments on nontransgenic cells treated with either Adeno-Cre or Adeno-GFP ( Figure 2a , left and middle) and no significant difference was noted in the various assays.
To assess whether postnatal cNSCs lacking Rb and p53 were able to function as medulloblastoma-initiating cells in vivo, we injected the cells subcutaneously into the flanks of NOD SCID mice. This strategy has been recently reported to efficiently sustain medulloblastoma growth (Zhao et al., 2008) and was chosen to permit injection of a large number of cells. Of 34 mice injected with cNSCs, 5 (14.7%) developed tumors (Figure 3a , left) between 67 and 81 days after injection, whereas no tumor growth was detected when control GFP-infected NS were injected. Whole-mount X-gal staining confirmed that neoplasms originated from the injected cells (Figure 3a) . The histological characteristics of the tumors were high cellularity, high nuclear/cytoplasmic ratio, moderate nuclear pleomorphism, nuclear molding and high mitotic and apoptotic activities (Figure 3a) . Immunohistochemistry revealed strong and homogeneous positivity for Synaptophysin, neuron-specific enolase and Map2 (Figure 3a ) in the majority of the tumor cells, whereas GFAP was decorating only few isolated cells (data not shown). Morphological and immunohistochemical features were those of a medulloblastoma with diffuse anaplasia.
To further substantiate our conclusion that the tumors were indeed originating from progenitors of non-granule cell lineage, we set out to assess expression of Math1 in the transformed cells at the time we would inject them subcutaneously (transformed preinjection cNSC, n ¼ 2), in cNSC medulloblastomas (n ¼ 3) and in EGL medulloblastomas (n ¼ 3) arising in Rb;p53
Figure 3 (a) Subcutaneous tumor arising 67 days after injection of cNSCs lacking Rb/p53 in an R26R-LacZ background into NOD SCID mice (left) originates from cNSCs, as assessed by X-gal staining. Histological features (hematoxylin and eosin) and marker expression (Synaptophysin, neuron-specific enolase and Map2) confirmed the diagnosis of medulloblastoma. (b) qRT-PCR analysis shows no significant difference in Math1 expression levels between transformed preinjection cNSC and cNSC medulloblastomas and tissue known not to express Math1 such as adult cerebellum and adult skeletal muscle. Expression of Math1 is high in EGL medulloblastomas and in ptc þ /À medulloblastomas. (c) No expression of GABARa6 and only very weak expression of Gli1 in all three cNSC medulloblastomas and high expression of the genes in the adult cerebellum and in 2 out of 3 EGL medulloblastomas. Scale bar is 4 mm, 1 mm and 125 mm respectively. conditional mutant mice. Expression of Math1 in the adult cerebellum (n ¼ 3) or in the adult skeletal muscle (n ¼ 1) and in medulloblastomas originating in ptc þ /À mice (n ¼ 3) was used as negative and positive controls, respectively. No difference in Math1 expression level was found between transformed preinjection cNSC and cNSC medulloblastomas and tissue known to not express Math1 such as adult cerebellum and adult skeletal muscle (Figure 3b ). On the contrary the expression of Math1 in EGL medulloblastomas was high and very similar to the expression levels detected in PTC þ /À medulloblastomas (Figure 3b) . Similarly no expression of GABARa6 and only very weak expression of Gli1 was detected in all three cNSC medulloblastomas as compared to the strong expression of both genes in the adult cerebellum and in 2 out of 3 EGL medulloblastomas (Figure 3c) . Interestingly, expression of ptch2 and N-Myc, which we found significantly upregulated in EGL medulloblastoma (Shakhova et al., 2006) , was significantly lower in cNSC medulloblastoma (Supplementary Figure S3 ), therefore implying that a different molecular mechanism might be involved in the pathogenesis of these tumors.
To determine whether the expression of stem cell markers could be useful in discriminating between medulloblastomas arising from cNSC and those originating from GCPs, we tested expression of two such markers, Sox2 and Sox9 (Cheung and Briscoe, 2003; Ellis et al., 2004; Ferri et al., 2004) on three cNSC medulloblastomas and on a tissue microarray (TMA) containing 24 murine EGL medulloblastomas originating from GCPs that lacked Rb and p53 (Marino et al., 2000) .
We found strong and homogeneous expression of Sox2 and Sox9 in the majority of cells of cNSC medulloblastomas (95% positive cells) as well as expression of Nestin (which is only weakly expressed in GCPs) in a significant proportion of tumor cells (60% positive cells; Figure 4a upper row). Conversely, expression of these markers was not seen in the vast majority of the tumor cells of EGL medulloblastomas, where they decorated only few scattered cells within the tumor (5% positive cells; Figure 4a lower row). Western blot analysis of six of these EGL medulloblastomas confirmed absence of Sox2 expression (Figure 4b) . Moreover, another example of medulloblastoma arising from GCPs in ptc þ /À mice displayed comparable results with only few scattered cells that were positive for Sox2 (Figure 4c ).
Then we analyzed the expression of Sox2 and Sox9 in the developing cerebellum of nontransgenic mice. At embryonic day (E) 18.5 we found strong expression of both markers in all cells of the NE (Figure 4d upper row) whereas GCPs of the EGL were mainly negative with only few of these cells expressing these markers very weakly (Figure 4d lower row and inset) . At the peak of the clonal expansion phase of GCPs (P7), no expression was seen in these highly proliferating cells, whereas Bergmann glia cells and scattered cells within the internal granular layer (IGL) and in the white matter expressed Sox2 and Sox9 (Figure 4e and data not shown) .
A fraction of these cells was also proliferating, as assessed by BrdU staining (Figure 4e ) and was coexpressing Nestin (Figure 4e) . Later, when the development of the cerebellum is complete (P20), Sox2 þ cells were still present in the same anatomical locations as described at P7 (Figure 4f) .
These results raise the possibility that expression of stem cell markers such as Sox2, Sox9 and potentially Nestin identifies medulloblastoma arising from cNSCs, in keeping with the developmental expression profile of these markers.
Next, we analyzed whether NE stem cell markers were expressed in human medulloblastoma. Sox2 was chosen, because its expression has been more consistently linked to non-granule cell progenitors (Sottile et al., 2006) and NSCs (Suh et al., 2007) . Western blot analysis revealed expression of Sox2 in 5 out of 13 medulloblastoma samples (Figure 5a ) but no significant expression in three medulloblastoma cell lines (DAOY, D341 and D458). Similar expression of Sox2 was found in the majority of glioblastomas (unrelated malignant CNS tumors of astrocytic lineage) analyzed (Figure 5a ). To scale-up the analysis and to correlate Sox2 expression to specific histological and biological parameters, we generated a TMA from 71 human medulloblastoma samples. Eighteen cases showed widespread nuclear positivity for Sox2, whereas 53 cases were negative. Interestingly, a statistically significant higher number of Sox2 þ medulloblastomas was found in the adult population, whereas Sox2 À tumors were more frequent in children (63 and 14% Sox2 þ cases, respectively; P ¼ 0.0001). We found that the majority of Sox2 þ cases were also expressing Nestin (67%, P ¼ 0.0331), whereas no coexpression of Sox2 and GFAP was found (Figure 5c ).
Expression analysis has shown activation of the Shh pathway in the majority of human medulloblastomas (Pomeroy et al., 2002) , despite the fact that mutations in members of the pathway are only found in a subset of tumors. To assess Shh pathway activation, we performed RNA in situ hybridization for Gli1 (Figure 5b ) and immunohistochemistry for Bcl2 (Figure 5b ) and found 39 (55%) and 25 (35%) positive cases, respectively. Medulloblastomas expressing Gli1 were frequently coexpressing Bcl2 (49 versus 4.5% Bcl2 þ cases in the Gli1 À group, P ¼ 0.0013), in keeping with the interpretation of their expression to indicate Shh pathway activation (Lee et al., 1997; Bigelow et al., 2004; Bar et al., 2007) . The positive correlation between expression of Gli1 and Math1, which characterizes medulloblastomas originating from EGL progenitor cells (P ¼ 0.0057) is in keeping with the notion that deregulation of the Shh pathway has a crucial role in the pathogenesis of medulloblastomas arising from the EGL (Taylor et al., 2002; Romer et al., 2004; Kimura et al., 2005) . Surprisingly, a significant association was found also between expression of Sox2 and expression of Gli1 (94%, P ¼ 0.003) as well as Bcl2 (83%, P ¼ 0.0001). On the contrary, Gli1 was found to be expressed at even lower level than in the adult cerebellum in our allograft model. These data together with the lack of Math1 expression in both murine cNSC medulloblastoma and in human Sox2 þ medulloblastoma suggest aberrant activation of the Shh pathway independently of granule cell commitment in human medulloblastomas. In keeping with this interpretation, a crucial role of Shh in controlling the behavior of cells with stem cell properties in the mouse embryonic neocortex (Palma and Ruiz i Altaba, 2004 ) and the proliferation of NSC in the adult murine brain (Palma et al., 2005) has been shown.
Nuclear b-catenin immunoreactivity, indicative of Wnt/Wg activation, as well as mutations affecting components of this pathway have been reported in 25 and 15% of cases of human medulloblastomas, respectively (Huang et al., 2000; Ellison et al., 2005) . Moreover, an association between mutations in this pathway and a putative origin of this subgroup of tumors from NSCs has been hypothesized (Gilbertson and Ellison, 2008) . We found strong nuclear positivity for b-catenin (Figure 5b ) in a majority of tumor cells only in three cases and none of them expressed Sox2. Moreover, no nuclear expression of b-catenin was seen in murine cNSC medulloblastoma (data not shown).
Furthermore, we set out to analyze whether the expression of stem cell markers Sox2 and Nestin either alone or in combination would influence disease progression and survival. Pediatric patients with Sox2 À medulloblastoma had a longer disease-free interval compared to those with Sox2 expression (Figure 5d , P ¼ 0.0015). A similar trend was observed also among the adult population, where the percentage of tumors expressing Sox2 was higher; however, the data did not reach statistical significance due to the smaller number of cases (Figure 5d ). Nestin expression alone was not significantly associated with clinical outcome. However, Postnatal cerebellar stem cells and medulloblastoma R Sutter et al coexpression of Sox2 and Nestin was associated with a significantly shorter survival rate (Figure 5d , P ¼ 0.039). It is intriguing that double labeling for Sox2 and Nestin in postnatal human cerebellum showed scattered cells expressing both markers within the cerebellar white matter (Figure 5e ) as observed in the mouse cerebellum (Figure 4f ). These findings suggest that cells with stem cell properties might exist in the postnatal human cerebellum and they might be involved in medulloblastoma pathogenesis as we have shown in our mouse model.
Discussion
We show here that inactivation of the tumor suppressor genes Rb and p53 in postnatal cNSCs induces deregulated proliferation and resistance to apoptosis in vitro and leads to medulloblastoma formation upon injection of these cells into mice. Experimental medulloblastoma originating from cNSCs do not express granule cell markers, such as Math1, Gli1 and GABARa6, but preferentially express stem cell markers Nestin, Sox2 Postnatal cerebellar stem cells and medulloblastoma R Sutter et al and Sox9. Furthermore, the expression of these markers identifies a subset of human medulloblastomas associated with a poorer clinical outcome. cNSCs can be efficiently isolated from the postnatal murine cerebellum by means of magnetic-activated cell sorting for CD133 followed by several dissociation/ replating rounds under NS-forming culturing conditions. Although these cells are likely to represent the cells described by the Wechsler-Reya group, which are located in the white matter and at the boundary between IGL and white matter (Lee et al., 2005) , we cannot exclude that also periventricular cells of the fourth ventricle are contained in our preparation. Bergmann glia cells, which also express Sox2 (Sottile et al., 2006) , are unlikely to be contained in the cNSC preparation as they do not express CD133 (GENSAT) and therefore would not have been enriched for with our method. Moreover, expression of GFAP was found not to colocalize with expression of Sox2 in the tumor samples.
We show that both granule cell progenitors (Marino et al., 2000) and precursors of non-granule cell lineage (CD133 þ , Math1 À ) can give rise to medulloblastoma in mouse models upon inactivation of Rb and p53. However, despite this common genetic substrate, different pathways appear to be involved in the formation of tumors from different cells of origin. Sox2 and Sox9 are strongly expressed in cNSC medulloblastoma whereas N-Myc, Gli1 and ptc2 are not. Conversely, the latter are strongly expressed in EGL medulloblastoma. These data imply that, in the mouse, a Shh-independent mechanism drives medulloblastoma formation from non-granule cell progenitors. Indeed, previous work has shown that despite targeting Shh activation to NSCs during embryonic development, acquisition of granule cell precursor identity was needed for Shh-promoted medulloblastoma formation (Schuller et al., 2008; Yang et al., 2008) . Taken together these data support the notion that different combinations of genetic mutations are needed to transform cells at different developmental stages.
The tumor incidence upon injection of Rb
cNSCs was low, as compared to the very high incidence of medulloblastomas when GCPs were targeted. This might imply that either cNSCs have protective mechanisms in place to prevent their neoplastic transformation or that the microenvironment has an important influence on tumor growth. Our experimental setting did not allow us to inject subcutaneously the CD133 À fraction as these cells are mainly GCPs that become postmitotic when cultured. To induce recombination in vitro by means of Adeno-Cre infection, we would have had to passage them. However, Zhao et al. (2008) have shown efficient subcutaneous medulloblastoma growth, therefore raising the possibility that a cell intrinsic mechanism might be involved in the low tumor take. Medulloblastomas show a heterogeneous biological behavior in human, which is reflected in the wide spectrum of clinical outcome and response to therapy. Despite considerable progress in the clinical management of these patients, which resulted in an improvement of overall survival, the long-term side effects of the aggressive therapeutic regimen used are often severe. Here we show that expression of NE stem cell markers identifies a subset of medulloblastomas associated with a worse clinical outcome. These data raise the possibility that the genetic make up of the cell of origin determines to certain extent the clinical heterogeneity of histologically similar medulloblastomas. Interestingly, these tumors were more often found among the adult population, indeed expression of Sox2 and Math1 (data not shown), which is expressed in medulloblastomas originating from EGL GCPs also in human (Lee et al., 2003; Zhao et al., 2008) , was mutually exclusive in our tumor series. A recent study showed similar robust positivity for Sox2 in glial tumors, which was associated with the expression of glial-specific markers (Phi et al., 2008) . However, we found no coexpression of Sox2 and GFAP in our series of medulloblastomas, suggesting that Sox2 expression in medulloblastomas is restricted to a subset of tumors, in agreement with previous data (Shu et al., 2008; de Bont et al., 2008) and not a general phenomenon related to glial differentiation as in glioblastoma.
Surprisingly, in human samples, increased expression of Gli1 was also seen in medulloblastomas expressing strong and homogeneous levels of Sox2 in the majority of tumor cells. Although we do not currently have a good explanation for this finding, it can be speculated that, in human, aberrant activation of the Shh pathway has a role also in stem cell-derived medulloblastomas.
Understanding the ontogeny and the closely linked molecular mechanisms involved in medulloblastoma pathogenesis is key to achieve a better therapeutic stratification of patients and to identify novel drugable targets to improve the outcome of these highly aggressive neoplasms.
Materials and methods

Mouse strains Rb loxP/loxP
; p53 loxP/loxP ;R26R-LacZ homozygous mutant mice and Math1GFP transgenic mice were used (Marino et al., 2000; Lumpkin et al., 2003) . Allograft studies were performed in NOD SCID mice. All procedures had Home Office approval (PPL 70/6452). cNSC isolation, culture and LoxP sites recombination Pups were decapitated at P7 and single cells were prepared from the cerebellum using the neural tissue dissociation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) . To enrich for cNSCs, magnetic-activated cell sorting for Prominin1 (Miltenyi Biotec) was used. Flow cytometry after immunolabeling of the cells with Prominin1-APC-antibodies (Miltenyi) showed a 10-fold enrichment of the CD133 þ cells, in agreement with published data (Pfenninger et al., 2007) . Flow cytometry for GFP on CD133 þ and CD133 À fractions isolated from Math1-GFP cerebella revealed a percentage of GFP þ cells of 34.2 and 93.3%, respectively. Culturing conditions: Dulbecco's modified Eagle's medium/HamF12 medium (Invitrogen Ltd, Paisley, UK), 1% Pen/Strep (Invitrogen), 20 ng/ml EGF/ bFGF (PeproTech EC Ltd, London, UK) and 2% B27 (Invitrogen). Cells were grown at 37 1C and 5% CO 2 . EGF and bFGF was supplemented every 3 days at 20 ng/ml. NS were repeatedly dissociated-at least three times-mechanically to single cells and replated in fresh medium before any assay was carried out. Flow cytometry for GFP revealed no positive cells at this time point.
Deletion/inactivation of Rb and p53 was achieved in vitro by adenoviral-mediated Cre delivery in cNSCs isolated from Rb loxP/loxP ; p53 loxP/loxP ; RosaLacZ homozygous mice. Adenoviral vectors (Clontech Laboratories Inc., Mountain View, CA, USA) expressing Cre or GFP were used. The cells were infected with Adeno-Cre or Adeno-GFP at a multiplicity of infection of 2 (2.5 Â 10 6 PFU/ml) 1 day after mechanical dissociation. To assess the efficiency of recombination, we stained Adeno-Cre-infected cells with X-gal according to standard protocols. PCR analysis of Cre-mediated recombination was performed on genomic DNA extracted from NS isolated from heterozygous compound mutant mice according to published protocols (Marino et al., 2000) .
Characterization of mutant cNSC
Proliferation/viability was assessed with AlamarBlue assay (Biosource International Inc., Camarillo, CA, USA). 8000 cells per well were plated in a 96-well plate (BD Falcon, Franklin Lakes, NJ, USA) and proliferation was assessed daily for 7 days by measuring absorption at 570 nm. Self-renewal was evaluated by performing serial dilutions of cells (from 500 to 4 cells per well) in 24-well plates (BD Falcon) and counting the number of resulting NS in each well after 5 days in culture. The results were plotted into self-renewal bars. For analysis of apoptosis, 5 Â 10 5 cells were labeled with Annexin V (Invitrogen), dead cells were labeled with DAPI (Sigma-Aldrich Company Ltd., Dorset, UK); flow cytometry was performed with a LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and data calculated using the FACSDiva software (BD Biosciences).
For assessment of multipotency, NS were seeded on laminin-coated coverslips and grown in Neurobasal medium (Invitrogen) supplemented with 1% B27 (Invitrogen) for 7 days. Undifferentiated NS were seeded on laminin-coated multichamber slides (BD Biosciences) for 20 min to induce adhesion and facilitate subsequent processing. Both undifferentiated NS and differentiated cells were fixed in 4% paraformaldehyde. See Supplementary Material for list of antibodies.
NS were dissociated mechanically 1 day before subcutaneous injection. RbÀ/À; p53 À/À cNSCs (250 000) were injected subcutaneously into the right flank of the animal, whereas GFP-infected or -uninfected control cNSCs were injected into the left flank. Palpable tumors were surgically removed upon killing the animal with CO 2 . All animals were killed 140 days after injection. X-gal staining was performed according to standard protocols. Tumors were fixed in 4% buffered formalin, embedded in paraffin, cut and processed according to standard protocols.
Expression analysis on cNSC and murine tumors by qRT-PCR or RT-PCR RNA from adult cerebellum as well as tumors were extracted using the Trizol method according to standard protocols and DNase treated using Amp Grade DNase I (Invitrogen) according to the manufacturer's descriptions. RNA from preinjection tertiary NS-derived cells was extracted using the Qiagen RNeasy Micro Kit (Qiagen Ltd., Crawley, West Sussex, UK) and on-column DNase treatment was performed according to the manufacturer's descriptions. First-strand cDNA synthesis was carried out using the Superscript III Reverse Transcriptase kit (Invitrogen). The expression levels of Math1, Bcl-2 and N-myc were compared using SYBR Green (Sigma) qRT-PCR on a 7500 ABI machine with previously published primers (Nmyc; Yang et al., 2008) or the following primers: Bcl-2, Forward: GAGCGTCAACAGGGAGATGT, Reverse: CTCACTTGTGGCCCAGGTAT; Math1, Forward: ACATCTCCCAGATCCCACAG, Reverse: ACAACGAT-CACCACAGACCA. Expression of the following genes was detected using RT-PCR and the following published or newly designed primers: GABARa6 (Drescher et al., 1993) ; Gli1 (Yang et al., 2008) ; Ptc-2, Forward: TGGCTTCGAGCT TACTTCCA, Reverse: CCCAGCTTCTCCTTGGTGTA; ActB, Forward: TGTTACCAACTGGGACGACA, Reverse: GGGGTGTTGAAGGTCTCAAA.
Histological analysis
Ethical approval was obtained from the SPUK Zurich (StV 6-2005) for the studies on human medulloblastomas. Medulloblastomas obtained from the archives of the Pathology Department of the University Hospital of Zurich and the Cantonal Hospital of Aarau, Switzerland, between 1986 and 2004 were used to construct TMA. Sixty-six samples were primary neoplasms and five were recurrences.
All histological slides were independently reevaluated by two neuropathologists. Five human tumors were nodular/desmoplastic and eight were large-cell anaplastic variant, all other specimens were classified as classic type. Survival data with a medium follow-up period of 66 months (range 1-189 months), progression data, and M stage were available from 56 patients. There were 44 pediatric (o16 years) and 18 adult (X16 years) cases. The age of three patients was unknown. Two cores (0.6 mm in diameter each) from representative areas were taken for each medulloblastomas and the presence of tumor cells was confirmed on a hematoxylin-and-eosin-stained slide of the TMA. See Supplementary Material for list of antibodies.
Statistics
Contingency table analysis and w
2
-tests were applied to study the relationship between protein expression, histological, biological and clinical parameters. Survival curves were plotted according to the Kaplan-Meier method. A log-rank test was applied to examine the relationship between molecular data and tumor-specific survival or tumor progression. For progression analysis, patients were censored at the time of their last clinical control showing no evidence of progressed disease. For tumor-specific survival analysis, patients were censored at the time of their last clinical control. All statistics were performed using StatView 5.0.1 and SPSS 12.0.1 for Windows.
